DiaSorin

DiaSorin S.p.A. is an Italian multinational biotechnology company specializing in the development, manufacturing, and marketing of in vitro diagnostic reagents. Established in 2000, the company has become a global leader in the diagnostics sector. It offers a comprehensive range of diagnostic tests and solutions.

Product and Service Offerings

DiaSorin's product portfolio includes both immunodiagnostic and molecular diagnostic tests, addressing many medical conditions.

In immunodiagnostics, the company provides assays for infectious diseases, bone and mineral metabolism, endocrinology, hypertension, oncology, gastrointestinal infections, autoimmunity, and brain and cardiac markers.

These tests detect specific antibodies and antigens to aid in diagnosis and health condition monitoring.

In molecular diagnostics, DiaSorin focuses on detecting DNA and RNA sequences of clinically relevant pathogens. This includes tests for infectious diseases and certain leukemias using blood, cerebrospinal fluid, and swab samples.

A major advancement was the acquisition of Luminex Corporation in July 2021, expanding capabilities in the Life Science sector. This introduced technologies like Multi-Analyte Profiling (xMAP) and Flow Cytometry.

These innovations enhance its diagnostic solutions and support pharmaceutical product development.

Technological Platforms

DiaSorin's diagnostic tests run on proprietary platforms developed with partners. Immunodiagnostic platforms are based on Chemiluminescent Immunoassay (CLIA) and Enzyme-Linked Immunosorbent Assay (ELISA) technologies.

Molecular diagnostic platforms cover the entire workflow, including extraction, amplification, and detection.

Global Presence

With a workforce of over 3,200 employees, including more than 400 researchers, DiaSorin operates across five continents.

The company maintains 10 manufacturing facilities and 9 research and development centers worldwide.

In the United States, key production sites include:

• Stillwater, Minnesota
• Garden Grove, California

Commitment to Innovation

DiaSorin invests continuously in research and development to innovate advanced diagnostic solutions that enhance patient care.

The company aims to address evolving healthcare needs and support new therapeutic developments.

In summary, DiaSorin stands as a prominent biotechnology company, delivering diverse diagnostic tests worldwide.

Through acquisitions, advanced technologies, and a global footprint, the company significantly contributes to medical diagnostics.